According to Haohai Biotech's announcement, the company repurchased 48,000 H shares through the Hong Kong Stock Exchange on September 10, 2026. The repurchase price range for each share was HK$16.47 to HK$16.76. The total repurchase amount was HK$79,5745, accounting for 0.0213% of the H shares issued prior to the relevant incident. The repurchased shares are to be cancelled and have not been cancelled as of September 10, 2026. The company's repurchase authorization was approved on May 29, 2026. The maximum number of H shares that can be repurchased is 347,8034 shares. Up to now, 807,500 shares have been repurchased, accounting for 2.3217% of the H shares issued on the date the authorization was approved. Matters such as the issuance of new shares after this repurchase will be suspended until October 10, 2026.

According to Haohai Biotech's announcement, the company repurchased 48,000 H shares through the Hong Kong Stock Exchange on September 10, 2026. The repurchase price range for each share was HK$16.47 to HK$16.76. The total repurchase amount was HK$79,5745, accounting for 0.0213% of the H shares issued prior to the relevant incident. The repurchased shares are to be cancelled and have not been cancelled as of September 10, 2026. The company's repurchase authorization was approved on May 29, 2026. The maximum number of H shares that can be repurchased is 347,8034 shares. Up to now, 807,500 shares have been repurchased, accounting for 2.3217% of the H shares issued on the date the authorization was approved. Matters such as the issuance of new shares after this repurchase will be suspended until October 10, 2026.